Full Text View
Tabular View
Study Results
Related Studies
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
This study has been completed.
Study NCT00481676   Information provided by Novartis

First Received on June 1, 2007.   Last Updated on September 14, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Urticaria
Additional conditions recognized in this trial
Urticaria
More general conditions related to this trial
Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases
Skin Diseases
Skin Diseases, Vascular
Interventions listed in this trial
Omalizumab 75-375 mg
Placebo to omalizumab
Loratadine
Clemastine
Additional drug interventions recognized in this trial
Omalizumab
More general drug interventions related to this trial
Anti-Allergic Agents
Anti-Asthmatic Agents
Antipruritics
Dermatologic Agents
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Histamine H1 Antagonists, Non-Sedating
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses
Sponsors listed in this trial
Novartis


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services